MedTrace Logo

Moderately Hypofractionated Radiotherapy for Prostate Cancer.

NCT03827616 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-04-08

No results posted yet for this study

Summary

Radiation therapy is one of the standard treatments for men with prostate cancer. Moderately hypofractionated radiotherapy has been established to be equivalent to standard fractionated radiotherapy in several large randomized clinical trials, however different hypofractionated regimens have been used in these studies. The two most common hypofractionated regimens are 70 Gy in 28 fractions and 60 Gy in 20 fractions, both are considered standard of care, however it is not unknown which regimen is better in terms of effectiveness and toxicity. The aim of this randomized controlled clinical trial is to compare the two hypofractionated radiotherapy regimens using Helical Tomotherapy.

Conditions

  • Prostatic Neoplasms
  • Genital Neoplasms

Interventions

RADIATION

Hypofractionated IMRT using helical Tomotherapy.

70 Gy in 28 fractions intensity-modulated radiotherapy (IMRT)

RADIATION

Hypofractionated IMRT using helical Tomotherapy.

60 Gy in 20 fractions intensity-modulated radiotherapy (IMRT) using helical Tomotherapy.

Sponsors & Collaborators

  • Tatarstan Cancer Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2029-02-01
Completion
2030-02-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827616 on ClinicalTrials.gov